News Data cues up AZ oral SERD filing in first-line breast cancer AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.
News End of the line for Sanofi's SERD amcenestrant as it fails f... Sanofi has called time on breast cancer candidate amcenestrant – at one time one of its top pipeline prospects – after it missed the mark in another clinical trial.
News Consolidation in psychedelics as atai pairs with Beckley Beckley Psytech has agreed to merge with atai Life Sciences in a deal that would bring together two psychedelic medicine pioneers.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.